ArticleChest2024
Association of Metabolic Syndrome With Risk of Lung Cancer: A Population-Based Prospective Cohort Study.
Article in Chest, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 40 citations in OpenAlex.
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Age- and sex-dependent associations of metabolic syndrome with colorectal cancer in the UK Biobank.British journal of cancer · 2026Article
- Phenolic Endocrine-Disrupting Chemical Exposure and Systemic Biomarker Variability in Patients with Lung Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- ASO Author Reflections: Is Intervening in Metabolic Syndrome a New Direction for Improving the Prognosis After Curative-Intent Resection of Perihilar Cholangiocarcinoma?Annals of surgical oncology · 2026Article
- Association Between Metabolic Syndrome and Long-Term Prognosis in Patients with Perihilar Cholangiocarcinoma Treated with Curative-Intent Resection: A Multicenter Study.Annals of surgical oncology · 2026Article
- Metabolic disease variants rewire gene regulation through disruption of DNA G-quadruplex structures.Genome biology · 2026Article
- Female-specific risk factors for lung cancer: insights from the All of Us Research Program.BMC public health · 2026Article
- Metabolic syndrome and risk of sepsis and sepsis-related mortality: evidence from two large prospective cohort studies.Military Medical Research · 2026Article
- Cardiovascular-kidney-metabolic health, genetic susceptibility, and incident cancer risk: a prospective UK biobank cohort and machine learning study.Frontiers in endocrinology · 2026Article
- Review
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Metabolic Syndrome and Outcome Predictions: Friends or Foes?Journal of cardiovascular development and disease · 2025Article
- Serum γ-glutamyl transferase as a novel risk indicator for lung cancer: insights from four million Koreans.Respiratory research · 2025Article
- Increased risk of lung cancer in individuals with preserved ratio impaired spirometry: a nationwide cohort study.Scientific reports · 2025Article
- Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery.Translational lung cancer research · 2025Article
- Comparison of the predictive value of 17 anthropometric in-dices for the prevalence of metabolic syndrome among Chinese residents: a cross-sectional study.Diabetology & metabolic syndrome · 2025Article
- Exploring the relationship between fat mass index and metabolic syndrome among cancer patients in the U.S: An NHANES analysis.Scientific reports · 2025Article
- Associations of combined lifestyle and metabolic risks with cancer incidence in the UK biobank study.BMC cancer · 2025Article
- Association of circulating metabolic biomarkers with risk of lung cancer: a population-based prospective cohort study.BMC medicine · 2025Article
- Hyperglycemia and Lung Cancer-A Possible Relationship.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundBoth the incidence of lung cancer and the prevalence of metabolic syndrome (MetS) have been increasing worldwide. The relationship between MetS and lung cancer remains controversial. RESEARCH QUESTION: What is the risk of lung cancer associated with MetS and its components? STUDY DESIGN AND
methodsMultivariable Cox regression models were used to estimate the hazard ratio (HR) of MetS-related variables on lung cancer risk, both overall and by histologic subtype, in the UK Biobank. Stratified analyses were conducted by sex, tobacco use status, and use of medication. HR curves were used to test the nonlinear associations between the metabolic markers and the risk of lung cancer.
resultsOf the 331,877 participants included in this study, a total of 77,173 participants had a diagnosis of MetS at enrollment. During a median follow-up of 10.9 years, lung cancer as the primary site developed in 2,425 participants. The HRs of MetS were 1.21 (95% CI, 1.09-1.33), 1.28 (95% CI, 1.10-1.50), and 1.16 (95% CI, 0.94-1.44) for the overall risk of lung cancer, adenocarcinoma, and squamous cell carcinoma, respectively. The HRs increased with the number of metabolic abnormalities from 1.11 to approximately 1.4 or 1.5 for those with one to five disorders. Positive association with lung cancer was observed for low high-density lipoprotein cholesterol (HDL-C), elevated waist circumference, and hyperglycemia. The relationship between MetS and lung cancer was modified by sex, with a stronger effect in female patients (P = .031). The risk of lung cancer resulting from MetS was elevated mainly among individuals who used tobacco, although the modification effect of tobacco use was not statistically significant. A nonlinear association was found between lung cancer and HDL-C, waist circumference, and glycated hemoglobin.
interpretationThe increased risk of lung cancer associated with MetS suggests the importance of taking metabolic status and markers into consideration for the primary prevention of lung cancer and the selection of high-risk populations for lung cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.